Teva Pharmaceutical Industries submits a BLA for its G-CSF XM02

[News]

Teva Pharmaceutical Industries Ltd., today announced the submission of a Biologics License Application (BLA) with the U.S. Food and Drug Administration (FDA) for XM02, a granulocyte colony-stimulating factor (G-CSF) for the reduction in the duration of severe neutropenia and the incidence of febrile neutropenia in patients treated with established myelosuppressive chemotherapy for cancer.

More... (http://www.news-medical.net/news/20091201/Teva-Pharmaceutical-Industries-submits-a-BLA-for-its-G-CSF-XM02.aspx)